161 related articles for article (PubMed ID: 21963773)
1. In vivo antitumor effect of cromolyn in PEGylated liposomes for pancreatic cancer.
Kim CE; Lim SK; Kim JS
J Control Release; 2012 Jan; 157(2):190-5. PubMed ID: 21963773
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
[TBL] [Abstract][Full Text] [Related]
3. Interstitial chemotherapy with ricin-loaded thermosensitive hydrogel in pancreatic cancer xenograft.
Chen ZK; Lin LW; Weng XH; Xue ES; Lin YH
Hepatobiliary Pancreat Dis Int; 2009 Aug; 8(4):418-23. PubMed ID: 19666413
[TBL] [Abstract][Full Text] [Related]
4. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models.
Arumugam T; Ramachandran V; Logsdon CD
J Natl Cancer Inst; 2006 Dec; 98(24):1806-18. PubMed ID: 17179482
[TBL] [Abstract][Full Text] [Related]
5. The bisphosphonate incadronate inhibits intraperitoneal dissemination in an in vivo pancreatic cancer model.
Takiguchi S; Nishino Y; Inoue K; Ikeda M; Kataoka Y; Matsusue K; Nishiyama K; Iguchi H
Oncol Rep; 2012 Jul; 28(1):111-6. PubMed ID: 22484715
[TBL] [Abstract][Full Text] [Related]
6. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
7. Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosis-inducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model.
Byeon HJ; Choi SH; Choi JS; Kim TH; Lee ES; Lee KC; Youn YS
Biomed Pharmacother; 2014 Feb; 68(1):65-9. PubMed ID: 24268811
[TBL] [Abstract][Full Text] [Related]
8. Designing and developing S100P inhibitor 5-methyl cromolyn for pancreatic cancer therapy.
Arumugam T; Ramachandran V; Sun D; Peng Z; Pal A; Maxwell DS; Bornmann WG; Logsdon CD
Mol Cancer Ther; 2013 May; 12(5):654-62. PubMed ID: 23303403
[TBL] [Abstract][Full Text] [Related]
9. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
10. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Wang W; Adachi M; Zhang R; Zhou J; Zhu D
Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
[TBL] [Abstract][Full Text] [Related]
11. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.
Stover TC; Sharma A; Robertson GP; Kester M
Clin Cancer Res; 2005 May; 11(9):3465-74. PubMed ID: 15867249
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models.
Kaminskas LM; McLeod VM; Kelly BD; Cullinane C; Sberna G; Williamson M; Boyd BJ; Owen DJ; Porter CJ
Mol Pharm; 2012 Mar; 9(3):422-32. PubMed ID: 22233281
[TBL] [Abstract][Full Text] [Related]
13. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
Hao YL; Deng YJ; Chen Y; Wang KZ; Hao AJ; Zhang Y
J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756
[TBL] [Abstract][Full Text] [Related]
14. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin.
Wei M; Xu Y; Zou Q; Tu L; Tang C; Xu T; Deng L; Wu C
Eur J Pharm Sci; 2012 Jun; 46(3):131-41. PubMed ID: 22369856
[TBL] [Abstract][Full Text] [Related]
16. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers.
Gründker C; Ernst J; Reutter MD; Ghadimi BM; Emons G
Oncol Rep; 2011 Sep; 26(3):629-35. PubMed ID: 21667032
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo anticancer efficacy of silibinin against human pancreatic cancer BxPC-3 and PANC-1 cells.
Nambiar D; Prajapati V; Agarwal R; Singh RP
Cancer Lett; 2013 Jun; 334(1):109-17. PubMed ID: 23022268
[TBL] [Abstract][Full Text] [Related]
18. Triptolide augments the effects of 5-lipoxygenase RNA interference in suppressing pancreatic tumor growth in a xenograft mouse model.
Ding X; Zhou X; Zhang H; Qing J; Qiang H; Zhou G
Cancer Chemother Pharmacol; 2012 Jan; 69(1):253-61. PubMed ID: 21713446
[TBL] [Abstract][Full Text] [Related]
19. Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from Rheum officinale Baill, against pancreatic cancer in mice via inhibition of Akt activation.
Wei WT; Chen H; Ni ZL; Liu HB; Tong HF; Fan L; Liu A; Qiu MX; Liu DL; Guo HC; Wang ZH; Lin SZ
Int J Oncol; 2011 Dec; 39(6):1381-90. PubMed ID: 21805032
[TBL] [Abstract][Full Text] [Related]
20. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor.
Yan Z; Wang F; Wen Z; Zhan C; Feng L; Liu Y; Wei X; Xie C; Lu W
J Control Release; 2012 Jan; 157(1):118-25. PubMed ID: 21827801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
